002007 华兰生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.89413.61911.48916.37422.927
总资产报酬率 ROA (%)2.7739.6058.19112.04018.308
投入资产回报率 ROIC (%)3.55012.35710.27914.93722.160

边际利润分析
销售毛利率 (%)50.69169.59066.06468.73772.702
营业利润率 (%)32.61139.28231.53638.24042.811
息税前利润/营业总收入 (%)31.80638.86231.83638.27742.532
净利润/营业总收入 (%)27.15432.97927.62032.77836.713

收益指标分析
经营活动净收益/利润总额(%)74.25892.26298.279101.94097.056
价值变动净收益/利润总额(%)16.33910.08810.0855.9365.157
营业外收支净额/利润总额(%)-0.944-0.9990.273-0.484-0.145

偿债能力分析
流动比率 (X)3.8633.6133.7603.0933.919
速动比率 (X)3.0402.9653.0862.4803.307
资产负债率 (%)15.55116.66917.18021.4370.193
带息债务/全部投入资本 (%)8.3507.7149.31310.3985.753
股东权益/带息债务 (%)1,088.1141,185.620965.910854.7241,633.473
股东权益/负债合计 (%)462.616423.133410.537337.093388.425
利息保障倍数 (X)-63.607-1,241.805148.579173.116-195.772

营运能力分析
应收账款周转天数 (天)220.324152.549161.858145.41297.405
存货周转天数 (天)397.070345.746329.435328.805306.410